Last reviewed · How we verify

Mercaptopurine (Purinethol) — Competitive Intelligence Brief

Mercaptopurine (Purinethol) (Mercaptopurine (Purinethol)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Purine analog antimetabolite. Area: Oncology; Immunology.

phase 3 Purine analog antimetabolite HGPRT (hypoxanthine-guanine phosphoribosyltransferase); inosinate dehydrogenase Oncology; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Mercaptopurine (Purinethol) (Mercaptopurine (Purinethol)) — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Mercaptopurine is a purine analog that inhibits de novo purine synthesis and is converted to active metabolites that interfere with DNA and RNA synthesis, leading to cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mercaptopurine (Purinethol) TARGET Mercaptopurine (Purinethol) Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) phase 3 Purine analog antimetabolite HGPRT (hypoxanthine-guanine phosphoribosyltransferase); inosinate dehydrogenase
6MP 6MP South China Children's Leukemia Group marketed Purine analog antimetabolite Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH)
Fludarabine (Bayer) Fludarabine (Bayer) Chinese PLA General Hospital marketed Purine analog antimetabolite Ribonucleotide reductase, DNA polymerase
Fludarabine (Flud) Fludarabine (Flud) Technische Universität Dresden marketed Purine analog antimetabolite Ribonucleotide reductase, DNA polymerase
Fludarabine mono Fludarabine mono German CLL Study Group phase 3 Purine analog antimetabolite Ribonucleotide reductase; DNA polymerase
Fludarabine Injection Fludarabine Injection University of California, San Francisco phase 3 Purine analog antimetabolite Ribonucleotide reductase, DNA polymerase
Mercaptopurine, Imatinib Mercaptopurine, Imatinib St. Jude Children's Research Hospital phase 3 Purine analog antimetabolite and tyrosine kinase inhibitor combination Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Purine analog antimetabolite class)

  1. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 drug in this class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
  3. Chinese PLA General Hospital · 1 drug in this class
  4. French Innovative Leukemia Organisation · 1 drug in this class
  5. German CLL Study Group · 1 drug in this class
  6. National Cancer Institute (NCI) · 1 drug in this class
  7. South China Children's Leukemia Group · 1 drug in this class
  8. Technische Universität Dresden · 1 drug in this class
  9. University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mercaptopurine (Purinethol) — Competitive Intelligence Brief. https://druglandscape.com/ci/mercaptopurine-purinethol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: